Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Randomized,Double-Blind,Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZSP1603 in Chinese Healthy Subjects

NCT03619616 is registered in ClinicalTrials.gov with Guangdong Zhongsheng Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT03619616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03619616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Randomized,Double-Blind,Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZSP1603 in Chinese Healthy Subjects
Lead sponsor
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
July 16, 2018
Completion date
October 22, 2019
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis(ipf), solid tumor